Obagi Subject of Bidding War and 2 Stocks at 52-Week Peaks
Obagi Medical Products (NASDAQ:OMPI): Closing price $
The potential acquisition of Obagi by Valeant Pharmaceuticals International (NYSE:VRX) and Merz Pharma Group, has turned into a bidding war, which is likely to affect Valeant’s guidance. Meanwhile, Obagi shares are not exactly being negatively impacted. Shares closed up 0.99 percent Thursday at $25.44, and have been traded between $10.70 and $25.50 the last 52 weeks.